ABBVIE INC (4AB.DE) Stock Fundamental Analysis

Europe • Frankfurt Stock Exchange • FRA:4AB • US00287Y1091

182.6 EUR
+4.4 (+2.47%)
Last: Feb 5, 2026, 07:00 PM
Fundamental Rating

5

4AB gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 84 industry peers in the Biotechnology industry. There are concerns on the financial health of 4AB while its profitability can be described as average. 4AB has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

6

1. Profitability

1.1 Basic Checks

  • 4AB had positive earnings in the past year.
  • In the past year 4AB had a positive cash flow from operations.
  • In the past 5 years 4AB has always been profitable.
  • Each year in the past 5 years 4AB had a positive operating cash flow.
4AB.DE Yearly Net Income VS EBIT VS OCF VS FCF4AB.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B

1.2 Ratios

  • 4AB has a Return On Assets of 1.75%. This is in the better half of the industry: 4AB outperforms 75.00% of its industry peers.
  • 4AB has a better Return On Invested Capital (15.64%) than 92.86% of its industry peers.
  • 4AB had an Average Return On Invested Capital over the past 3 years of 13.67%. This is in line with the industry average of 11.98%.
  • The 3 year average ROIC (13.67%) for 4AB is below the current ROIC(15.64%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 1.75%
ROE N/A
ROIC 15.64%
ROA(3y)5.07%
ROA(5y)5.21%
ROE(3y)80.76%
ROE(5y)70.31%
ROIC(3y)13.67%
ROIC(5y)12.68%
4AB.DE Yearly ROA, ROE, ROIC4AB.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 100

1.3 Margins

  • The Profit Margin of 4AB (3.94%) is better than 77.38% of its industry peers.
  • 4AB's Profit Margin has declined in the last couple of years.
  • 4AB has a Operating Margin of 33.05%. This is amongst the best in the industry. 4AB outperforms 88.10% of its industry peers.
  • 4AB's Operating Margin has declined in the last couple of years.
  • The Gross Margin of 4AB (71.16%) is better than 61.90% of its industry peers.
  • 4AB's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 33.05%
PM (TTM) 3.94%
GM 71.16%
OM growth 3Y-5.46%
OM growth 5Y-6.52%
PM growth 3Y-28.3%
PM growth 5Y-20.42%
GM growth 3Y0.39%
GM growth 5Y-1.92%
4AB.DE Yearly Profit, Operating, Gross Margins4AB.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), 4AB is creating value.
  • Compared to 1 year ago, 4AB has about the same amount of shares outstanding.
  • 4AB has more shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, 4AB has a worse debt to assets ratio.
4AB.DE Yearly Shares Outstanding4AB.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B
4AB.DE Yearly Total Debt VS Total Assets4AB.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50B 100B 150B

2.2 Solvency

  • An Altman-Z score of 2.32 indicates that 4AB is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • 4AB has a better Altman-Z score (2.32) than 71.43% of its industry peers.
  • 4AB has a debt to FCF ratio of 3.49. This is a good value and a sign of high solvency as 4AB would need 3.49 years to pay back of all of its debts.
  • 4AB's Debt to FCF ratio of 3.49 is amongst the best of the industry. 4AB outperforms 82.14% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 3.49
Altman-Z 2.32
ROIC/WACC1.85
WACC8.44%
4AB.DE Yearly LT Debt VS Equity VS FCF4AB.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20B 40B 60B

2.3 Liquidity

  • 4AB has a Current Ratio of 0.72. This is a bad value and indicates that 4AB is not financially healthy enough and could expect problems in meeting its short term obligations.
  • The Current ratio of 4AB (0.72) is worse than 77.38% of its industry peers.
  • 4AB has a Quick Ratio of 0.72. This is a bad value and indicates that 4AB is not financially healthy enough and could expect problems in meeting its short term obligations.
  • 4AB's Quick ratio of 0.60 is on the low side compared to the rest of the industry. 4AB is outperformed by 77.38% of its industry peers.
Industry RankSector Rank
Current Ratio 0.72
Quick Ratio 0.6
4AB.DE Yearly Current Assets VS Current Liabilites4AB.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B 40B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • 4AB shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -12.09%.
  • The Earnings Per Share has been growing slightly by 2.51% on average over the past years.
  • The Revenue has been growing slightly by 7.40% in the past year.
  • Measured over the past years, 4AB shows a quite strong growth in Revenue. The Revenue has been growing by 11.11% on average per year.
EPS 1Y (TTM)-12.09%
EPS 3Y-7.24%
EPS 5Y2.51%
EPS Q2Q%-38%
Revenue 1Y (TTM)7.4%
Revenue growth 3Y0.08%
Revenue growth 5Y11.11%
Sales Q2Q%9.1%

3.2 Future

  • 4AB is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.67% yearly.
  • Based on estimates for the next years, 4AB will show a small growth in Revenue. The Revenue will grow by 7.50% on average per year.
EPS Next Y0.09%
EPS Next 2Y19.77%
EPS Next 3Y17.02%
EPS Next 5Y13.67%
Revenue Next Year8.75%
Revenue Next 2Y9.23%
Revenue Next 3Y8.83%
Revenue Next 5Y7.5%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4AB.DE Yearly Revenue VS Estimates4AB.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 20B 40B 60B 80B
4AB.DE Yearly EPS VS Estimates4AB.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5 10 15 20

More info and screens

Find the best growth stocksShow best growing peers

6

4. Valuation

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 22.85, the valuation of 4AB can be described as rather expensive.
  • Based on the Price/Earnings ratio, 4AB is valued cheaper than 82.14% of the companies in the same industry.
  • 4AB is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 27.67, which is the current average of the S&P500 Index.
  • Based on the Price/Forward Earnings ratio of 14.87, the valuation of 4AB can be described as correct.
  • Based on the Price/Forward Earnings ratio, 4AB is valued cheaper than 92.86% of the companies in the same industry.
  • 4AB is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 27.20, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 22.85
Fwd PE 14.87
4AB.DE Price Earnings VS Forward Price Earnings4AB.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • 80.95% of the companies in the same industry are more expensive than 4AB, based on the Enterprise Value to EBITDA ratio.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of 4AB indicates a rather cheap valuation: 4AB is cheaper than 86.90% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 19.38
EV/EBITDA 15.43
4AB.DE Per share data4AB.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 -20 -40

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates 4AB does not grow enough to justify the current Price/Earnings ratio.
  • 4AB has a very decent profitability rating, which may justify a higher PE ratio.
  • A more expensive valuation may be justified as 4AB's earnings are expected to grow with 17.02% in the coming years.
PEG (NY)264.54
PEG (5Y)9.1
EPS Next 2Y19.77%
EPS Next 3Y17.02%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

6

5. Dividend

5.1 Amount

  • 4AB has a Yearly Dividend Yield of 3.14%.
  • 4AB's Dividend Yield is rather good when compared to the industry average which is at 0.66. 4AB pays more dividend than 96.43% of the companies in the same industry.
  • Compared to an average S&P500 Dividend Yield of 1.82, 4AB pays a better dividend.
Industry RankSector Rank
Dividend Yield 3.14%

5.2 History

  • On average, the dividend of 4AB grows each year by 7.72%, which is quite nice.
Dividend Growth(5Y)7.72%
Div Incr Years4
Div Non Decr Years4
4AB.DE Yearly Dividends per share4AB.DE Yearly Dividends per shareYearly Dividends per share 2020 2021 2022 2023 2024 2025 2026 2 4 6

5.3 Sustainability

  • 489.69% of the earnings are spent on dividend by 4AB. This is not a sustainable payout ratio.
  • The dividend of 4AB is growing, but earnings are growing more, so the dividend growth is sustainable.
DP489.69%
EPS Next 2Y19.77%
EPS Next 3Y17.02%
4AB.DE Yearly Income VS Free CF VS Dividend4AB.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B
4AB.DE Dividend Payout.4AB.DE Dividend Payout, showing the Payout Ratio.4AB.DE Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

ABBVIE INC

FRA:4AB (2/5/2026, 7:00:00 PM)

182.6

+4.4 (+2.47%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-31
Earnings (Next)02-04
Inst Owners75.04%
Inst Owner ChangeN/A
Ins Owners0.05%
Ins Owner ChangeN/A
Market Cap322.72B
Revenue(TTM)59.64B
Net Income(TTM)2.35B
Analysts78.38
Price Target213.08 (16.69%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 3.14%
Yearly Dividend5.24
Dividend Growth(5Y)7.72%
DP489.69%
Div Incr Years4
Div Non Decr Years4
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)1.85%
Min EPS beat(2)0.95%
Max EPS beat(2)2.75%
EPS beat(4)4
Avg EPS beat(4)1.21%
Min EPS beat(4)0.02%
Max EPS beat(4)2.75%
EPS beat(8)7
Avg EPS beat(8)0.95%
EPS beat(12)9
Avg EPS beat(12)0.65%
EPS beat(16)11
Avg EPS beat(16)0.49%
Revenue beat(2)1
Avg Revenue beat(2)-0.08%
Min Revenue beat(2)-0.79%
Max Revenue beat(2)0.63%
Revenue beat(4)2
Avg Revenue beat(4)0.22%
Min Revenue beat(4)-0.79%
Max Revenue beat(4)1.23%
Revenue beat(8)4
Avg Revenue beat(8)0.31%
Revenue beat(12)5
Avg Revenue beat(12)-0.17%
Revenue beat(16)5
Avg Revenue beat(16)-0.74%
PT rev (1m)0.06%
PT rev (3m)2.05%
EPS NQ rev (1m)-20.83%
EPS NQ rev (3m)-20.17%
EPS NY rev (1m)-6.72%
EPS NY rev (3m)-5.75%
Revenue NQ rev (1m)0.16%
Revenue NQ rev (3m)0.58%
Revenue NY rev (1m)0.01%
Revenue NY rev (3m)0.48%
Valuation
Industry RankSector Rank
PE 22.85
Fwd PE 14.87
P/S 6.4
P/FCF 19.38
P/OCF 18.29
P/B N/A
P/tB N/A
EV/EBITDA 15.43
EPS(TTM)7.99
EY4.38%
EPS(NY)12.28
Fwd EY6.73%
FCF(TTM)9.42
FCFY5.16%
OCF(TTM)9.99
OCFY5.47%
SpS28.55
BVpS-1.26
TBVpS-44.32
PEG (NY)264.54
PEG (5Y)9.1
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 1.75%
ROE N/A
ROCE 20.86%
ROIC 15.64%
ROICexc 16.59%
ROICexgc 572.43%
OM 33.05%
PM (TTM) 3.94%
GM 71.16%
FCFM 33%
ROA(3y)5.07%
ROA(5y)5.21%
ROE(3y)80.76%
ROE(5y)70.31%
ROIC(3y)13.67%
ROIC(5y)12.68%
ROICexc(3y)15.06%
ROICexc(5y)13.91%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)17.54%
ROCE(5y)16.27%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y-1.81%
ROICexc growth 5Y-14.87%
OM growth 3Y-5.46%
OM growth 5Y-6.52%
PM growth 3Y-28.3%
PM growth 5Y-20.42%
GM growth 3Y0.39%
GM growth 5Y-1.92%
F-Score7
Asset Turnover0.45
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 3.49
Debt/EBITDA 2.39
Cap/Depr 14.25%
Cap/Sales 1.97%
Interest Coverage 250
Cash Conversion 74.59%
Profit Quality 838.33%
Current Ratio 0.72
Quick Ratio 0.6
Altman-Z 2.32
F-Score7
WACC8.44%
ROIC/WACC1.85
Cap/Depr(3y)9.59%
Cap/Depr(5y)10.06%
Cap/Sales(3y)1.45%
Cap/Sales(5y)1.5%
Profit Quality(3y)361.43%
Profit Quality(5y)328.91%
High Growth Momentum
Growth
EPS 1Y (TTM)-12.09%
EPS 3Y-7.24%
EPS 5Y2.51%
EPS Q2Q%-38%
EPS Next Y0.09%
EPS Next 2Y19.77%
EPS Next 3Y17.02%
EPS Next 5Y13.67%
Revenue 1Y (TTM)7.4%
Revenue growth 3Y0.08%
Revenue growth 5Y11.11%
Sales Q2Q%9.1%
Revenue Next Year8.75%
Revenue Next 2Y9.23%
Revenue Next 3Y8.83%
Revenue Next 5Y7.5%
EBIT growth 1Y27.38%
EBIT growth 3Y-5.38%
EBIT growth 5Y3.87%
EBIT Next Year-0.19%
EBIT Next 3Y15.91%
EBIT Next 5Y10.95%
FCF growth 1Y-20.4%
FCF growth 3Y-6.75%
FCF growth 5Y6.9%
OCF growth 1Y-18.24%
OCF growth 3Y-6.19%
OCF growth 5Y7.14%

ABBVIE INC / 4AB.DE FAQ

What is the ChartMill fundamental rating of ABBVIE INC (4AB.DE) stock?

ChartMill assigns a fundamental rating of 5 / 10 to 4AB.DE.


What is the valuation status for 4AB stock?

ChartMill assigns a valuation rating of 6 / 10 to ABBVIE INC (4AB.DE). This can be considered as Fairly Valued.


How profitable is ABBVIE INC (4AB.DE) stock?

ABBVIE INC (4AB.DE) has a profitability rating of 6 / 10.


Can you provide the financial health for 4AB stock?

The financial health rating of ABBVIE INC (4AB.DE) is 3 / 10.


How sustainable is the dividend of ABBVIE INC (4AB.DE) stock?

The dividend rating of ABBVIE INC (4AB.DE) is 6 / 10 and the dividend payout ratio is 489.69%.